DETECT-ASCEND 2
Research type
Research Study
Full title
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
IRAS ID
311132
Contact name
Ashraf Azzabi
Contact email
Sponsor organisation
Exact Sciences Thrive LLC
Duration of Study in the UK
0 years, 10 months, 3 days
Research summary
This is a prospective, observational study of cancer and healthy subjects.
CancerSEEK is a blood test (also called a liquid biopsy) designed to detect multiple types of cancer at the earliest stages possible. The CancerSEEK test has been shown in both retrospective and prospective settings to be able to detect many different types of cancer for which routine, standard-of-care (SOC) screening modalities are not presently available (Cohen et al., 2018), (Lennon et al., 2020). CancerSEEK, as a minimally invasive multi cancer screening test, employed in a complimentary fashion with currently approved SOC cancer screening approaches may be able to
increase cancer detection rates.
The primary objective of this study is to obtain clinically characterized, whole blood specimens from cancer and healthy subjects to develop and
refine assays for cancer in the blood.
The study population will include male and female subjects ≥ 50 years of age.REC name
London - Harrow Research Ethics Committee
REC reference
22/PR/0153
Date of REC Opinion
18 Jul 2022
REC opinion
Further Information Favourable Opinion